CSPC Ouyi Pharmaceutical

• NCT07796477

  Phase 2, Not yet recruiting, 240 people, 1 Sept 2026

• A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid

  Phase 3, Not yet recruiting, 222 people, 3 Jun 2026

• A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes

  Phase 3, Active, not recruiting, 815 people, 18 Jun 2025

• NCT06921044

  Collaborator, Phase 2, Not yet recruiting, 33 people, 10 Apr 2025

• NCT06571461

  Phase 3, Not yet recruiting, 408 people, 26 Aug 2024

• NCT06225622

  Collaborator, Phase 1, Status unknown, 78 people, 26 Jan 2024

• NCT05843292

  Collaborator, Phase 4, Not yet recruiting, 48 people, 6 May 2023

• NCT05522192

  Collaborator, Phase 1/2, Status unknown, 70 people, 30 Aug 2022

• NCT05441761

  Collaborator, Phase 1/2, Status unknown, 60 people, 1 Jul 2022

• NCT05173246

  Collaborator, Phase 2, Recruiting, 43 people, 29 Dec 2021

• NCT05159193

  Collaborator, Phase 3, Recruiting, 372 people, 16 Dec 2021

• NCT05052931

  Collaborator, Phase 2, Status unknown, 10 people, 22 Sept 2021

• NCT05047991

  Phase 2, Status unknown, 153 people, 17 Sept 2021

• NCT05009953

  Phase 2, Terminated, 17 people, 18 Aug 2021

• NCT04661696

  Collaborator, Phase 2, Status unknown, 75 people, 10 Dec 2020

• NCT04159142

  Collaborator, Phase 2, Recruiting, 414 people, 12 Nov 2019

• NCT04138719

  Collaborator, Phase 2, Recruiting, 520 people, 24 Oct 2019

• NCT04135781

  Collaborator, Phase 3, Status unknown, 616 people, 23 Oct 2019

• NCT03929094

  Collaborator, Phase 2, Status unknown, 120 people, 26 Apr 2019

• NCT03802058

  Collaborator, Phase 2, Terminated, 24 people, 14 Jan 2019

Sources: clinicaltrials.gov